Insmed Incorporated (INSM) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Insmed Incorporated (INSM) surged +15.07% to $111.59 as options desks priced 72% call premium vs. 28% put protection around the $109 max-pain magnet. Solid 80% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Insmed (INSM) just combined a fresh earnings update with higher 2026 revenue guidance for its key therapies, giving investors new numbers to weigh against a still loss-making but evolving biopharma business. Recent actio
Insmed (NasdaqGS: INSM) reported the commercial launch of BRINSUPRI tablets in Japan for non cystic fibrosis bronchiectasis. BRINSUPRI is described as the first approved therapy in Japan for patients with non cystic fibr
Insmed Incorporated (INSM) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDTCompany ParticipantsWilliam Lewis - President, CEO & ChairmanSara...
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
For questions about this article or underlying research, email help@trefis.com.
Key TakeawaysInsmed shares jumped 12% after third-quarter revenue of $524. 4 million beat expectations, led by $400.
Insmed (NASDAQ:INSM) reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE. Chair and Chief Execut
BRINSUPRI revenue surged to $400.1 million, driving 268% total revenue growth year-over-year.
Premarket movers on Oct. 29, 2026 include NCPL, PCLA, INLF, NUWE, BURU, INSM, CROX, GKOS, MAX, PRCH, IOVA, XRX, FTNT, SFM, TWI, ALNY and NOW.
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +66.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INSM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INSM. Explore sector supply chains on /butterfly.
Why INSM Stock surged +15.07% Today — RQD Quant Desk Flash. Solid 80% profit margin (-35% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.